These findings identify an acetylation-modified transcription factor KLF5 as a key modulator of tumor cell plasticity in the development and outgrowth of PCa bone metastases, and provide a rationale for using docetaxel plus plerixafor in the treatment of PCa bone metastases expressing Ac-KLF5. Here, KLF5 is linked to posterior cortical atrophy.